Core Insights - Charlotte's Web reported a 4.7% year-over-year increase in Q4 2025 revenue, reaching $13.3 million, driven by direct-to-consumer sales and new product offerings [20][22] - The company is positioned for growth through participation in the CMMI Medicare pilot program, which aims to provide CBD access to senior patients [5][11] - A significant transaction with British American Tobacco (BAT) will strengthen the company's balance sheet by converting a $54 million convertible debenture and adding $10 million in equity investment [2][34] Financial Performance - For the full year 2025, consolidated net revenue was $49.9 million, a slight increase of 0.5% from $49.7 million in 2024, marking the first annual revenue growth since 2021 [27] - Gross profit for 2025 was $21.7 million, representing a gross margin of 43.5%, up from 42.8% in 2024 [28] - Total selling, general, and administrative expenses decreased by 21.2% to $42.0 million in 2025, reflecting successful cost optimization strategies [29] Operational Developments - The company completed the internalization of Brightside™ gummy production, with 75% of total gummy production expected to transition in-house by 2026 [19] - Charlotte's Web received zero findings in its latest NSF 455-2 Dietary Supplement cGMP audit, indicating high compliance readiness [19] - The company is advancing its cannabinoid pharmaceutical development through DeFloria, which achieved significant milestones in 2025, including FDA clearance for Phase 2 clinical trials of AJA001 [12][18] Regulatory and Market Position - The CMMI Medicare pilot program represents a landmark opportunity for Charlotte's Web to integrate CBD into the healthcare system for seniors [5][11] - The HEMP Act is expected to provide a federal legislative framework that supports the responsible production of full-spectrum CBD products, indicating positive regulatory momentum for the industry [9][10] - The company is well-positioned to capitalize on emerging botanical wellness opportunities as regulatory clarity advances, with expectations for improved cash flow performance [33]

Core Insights - Curanex Pharmaceuticals Inc. has engaged Strategic Investor Relations, LLC to enhance its visibility and investor engagement in the financial community [1][2] - The company is focused on developing botanical drugs for inflammatory diseases, with a robust pipeline targeting conditions such as Ulcerative Colitis, Atopic Dermatitis, and Gouty Arthritis [3][6] - Curanex's lead candidate, Phyto-N, is a botanical extract with a long history of use in China and is set for IND submission in 2026 [3][6] Company Overview - Curanex Pharmaceuticals is a developmental-stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases [6] - The company has validated Phyto-N's effects in animal models for six inflammatory diseases, with a primary focus on moderate to severe ulcerative colitis [7] Strategic Initiatives - The partnership with Strategic Investor Relations aims to refine communication strategies and enhance transparency with stakeholders [2][5] - Curanex's founders have a strong foundation in botanical drug innovation, leveraging over 30 years of clinical evidence from China to inform their development processes [4] Market Positioning - Curanex is positioned in the rapidly expanding botanical drug market, focusing on high-efficacy botanical drugs with de-risked clinical pathways [2][5] - The company aims to communicate its innovative pipeline and market opportunities more effectively to drive shareholder value [5]

As filed with the Securities and Exchange Commission on June 21, 2024 Registration Statement No. 333-277725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | --- | ...

As filed with the Securities and Exchange Commission on December 5, 2023 Registration Statement No. 333-274042 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ Jyong Biotech Ltd. (Exact name of Registrant as specified in its charter) ____________________________ Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 2834 | Not Applicable | | --- | ...